Elicio Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: March 31, 2025
By: /s/ Robert Connelly
Robert Connelly
Chief Executive Officer
Power of Attorney
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Robert Connelly, as his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, with full power to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Robert ConnellyRobert Connelly | Chief Executive Officer, President and Director | March 31, 2025 |
| (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer) | ||
| /s/ Jay Venkatesan, M.D. | Director | March 31, 2025 |
| Jay Venkatesan, M.D. | ||
| /s/ Julian Adams, Ph.D. | Director | March 31, 2025 |
| Julian Adams, Ph.D. | ||
| /s/ Carol Ashe | Director | March 31, 2025 |
| Carol Ashe | ||
| /s/ Yekaterina (Katie) Chudnovsky | Director | March 31, 2025 |
| Yekaterina (Katie) Chudnovsky | ||
| /s/ Robert R. Ruffolo, Jr., Ph.D. | Director | March 31, 2025 |
|---|---|---|
| Robert R. Ruffolo, Jr., Ph.D. | ||
| /s/ Karen Wilson | Director | March 31, 2025 |
| Karen Wilson | ||
| /s/ Allen Nissenson, M.D. | Director | March 31, 2025 |
| Allen Nissenson, M.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.